Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 93 total PSOs listed by AHRQ.

PLEASE NOTE: To search for a PSO by State, use the 2 letter state abbreviation. Example: Kansas = KS

Louisiana Alliance for Patient Safety PSO - P0186
Component of Parent Org(s):
  • Louisiana Hospital Association
Effective Date and Time of Initial Listing: November 8, 2016 12:01 AM ET
PSO Mailing Address: 9521 Brookline Ave, Baton Rouge, LA 70809
PSO Phone Number: 225-928-0026
Point of Contact: Angela Lockhart
Point of Contact Phone: 225-928-0026, ext. 223
Point of Contact Email: alockhart@lhaonline.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 11/08/2020 through 11/07/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
The Guthrie Clinic PSO - P0182
Component of Parent Org(s):
  • The Guthrie Clinic
Effective Date and Time of Initial Listing: October 26, 2016 12:01 AM ET
PSO Mailing Address: One Guthrie Square, Sayre, PA 18840
PSO Phone Number: 570-887-4772
Point of Contact: Susan Hohenhaus
Point of Contact Phone: 570-887-4977
Point of Contact Email: susan.hohenhaus@guthrie.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 10/26/2020 through 10/25/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: Yes